Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415552 | 0.78 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL5412276 | 0.75 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5410063 | 0.74 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL14545539 | 0.73 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5420394 | 0.72 | CRHR1 (0.81) | CRHR1 | |
| SCHEMBL5404391 | 0.69 | CRHR1 (0.43) | CRHR1KDM4E | |
| SCHEMBL4628910 | 0.67 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL4788652 | 0.67 | CNR1 (0.52) | CRHR1KDM4EMEN1ALDH1A1POLB | |
| SCHEMBL14544920 | 0.65 | CRHR1 (0.48) | CRHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4682587 | 0.64 | HTT (0.55) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CRHR1 96/4885KDM4E 1408/4885MEN1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.